Dennis Ding
Stock Analyst at Jefferies
(1.13)
# 3,769
Out of 5,005 analysts
15
Total ratings
40%
Success rate
-5.17%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Dennis Ding
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ROIV Roivant Sciences | Maintains: Buy | $18 → $20 | $16.17 | +23.69% | 2 | Sep 18, 2025 | |
| MLYS Mineralys Therapeutics | Maintains: Hold | $15 → $26 | $38.06 | -31.69% | 2 | Sep 3, 2025 | |
| INDV Indivior | Assumes: Buy | $20 | $23.17 | -13.68% | 1 | Jul 22, 2025 | |
| CRNX Crinetics Pharmaceuticals | Upgrades: Buy | $55 | $40.86 | +34.61% | 1 | Jan 22, 2025 | |
| IKT Inhibikase Therapeutics | Initiates: Buy | $8 | $1.66 | +381.93% | 1 | Nov 8, 2024 | |
| ASMB Assembly Biosciences | Upgrades: Buy | $2 → $35 | $23.32 | +50.09% | 1 | Sep 20, 2024 | |
| FOLD Amicus Therapeutics | Initiates: Buy | $18 | $8.20 | +119.51% | 1 | Sep 6, 2024 | |
| ABUS Arbutus Biopharma | Maintains: Buy | $5 → $7 | $4.38 | +59.82% | 2 | Sep 5, 2024 | |
| RXRX Recursion Pharmaceuticals | Maintains: Hold | $8 → $6 | $5.49 | +9.29% | 1 | Sep 3, 2024 | |
| LYRA Lyra Therapeutics | Downgrades: Hold | $500 → $25 | $7.00 | +257.14% | 1 | May 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $35 → $22 | $88.15 | -75.04% | 1 | Feb 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $30.67 | -21.75% | 1 | Dec 19, 2022 |
Roivant Sciences
Sep 18, 2025
Maintains: Buy
Price Target: $18 → $20
Current: $16.17
Upside: +23.69%
Mineralys Therapeutics
Sep 3, 2025
Maintains: Hold
Price Target: $15 → $26
Current: $38.06
Upside: -31.69%
Indivior
Jul 22, 2025
Assumes: Buy
Price Target: $20
Current: $23.17
Upside: -13.68%
Crinetics Pharmaceuticals
Jan 22, 2025
Upgrades: Buy
Price Target: $55
Current: $40.86
Upside: +34.61%
Inhibikase Therapeutics
Nov 8, 2024
Initiates: Buy
Price Target: $8
Current: $1.66
Upside: +381.93%
Assembly Biosciences
Sep 20, 2024
Upgrades: Buy
Price Target: $2 → $35
Current: $23.32
Upside: +50.09%
Amicus Therapeutics
Sep 6, 2024
Initiates: Buy
Price Target: $18
Current: $8.20
Upside: +119.51%
Arbutus Biopharma
Sep 5, 2024
Maintains: Buy
Price Target: $5 → $7
Current: $4.38
Upside: +59.82%
Recursion Pharmaceuticals
Sep 3, 2024
Maintains: Hold
Price Target: $8 → $6
Current: $5.49
Upside: +9.29%
Lyra Therapeutics
May 7, 2024
Downgrades: Hold
Price Target: $500 → $25
Current: $7.00
Upside: +257.14%
Feb 15, 2023
Downgrades: Hold
Price Target: $35 → $22
Current: $88.15
Upside: -75.04%
Dec 19, 2022
Initiates: Buy
Price Target: $24
Current: $30.67
Upside: -21.75%